"Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer".

ABSTRACT:

Background

ROS1 fusion is an infrequent, but attractive target for therapy in patients with metastatic non- small-cell lung cancer. In studies on mainly late-stage disease, the prevalence of ROS1 fusions is about 1-3%. In early-stage lung cancer ROS1 might also provide a fruitful target for neoadjuvant or adjuvant therapy. In the present study, we investigated the prevalence of ROS1 fusion in a Norwegian cohort of early-stage lung cancer. We also explored whether positive ROS1 immunohistochemical (IHC) stain was associated with certain mutations, clinical characteristics and outcomes.

Methods

The study was performed using biobank material from 921 lung cancer patients including 542 patients with adenocarcinoma surgically resected during 2006-2018. Initially, we screened the

SUBMITTER: Dyrbekk APH 

PROVIDER: S-EPMC10224579 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature